Country: New Zealand
Bahasa: Inggeris
Sumber: Ministry for Primary Industries
pimobendan
Boehringer Ingelheim Animal Health New Zealand Limited
pimobendan
pimobendan 2.5 g/kg
Cardiovascular agent
ACVM Registered
2007-01-10
Product: Vetmedin 5 mg Chewable Tablets for Dogs Date: 9 March 2018 ACVM No.: A009701 Page 1 of 6 BOTTLE LABEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Vetmedin ® 5 mg Chewable Tablets for Dogs Active Constituent: Each tablet contains 5 mg Pimobendan 50 tablets READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS. FIRST AID If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126. New Zealand 0800 764 766 (0800 POISON) STORAGE Store below 25 °C (Air Conditioning). Keep the container tightly closed. AUSTRALIA Boehringer Ingelheim Animal Health Australia Pty Limited Phone: 1800 038 037 APVMA 60798/XXXX/XXXX NEW ZEALAND INFORMATION RVM ACVM No. A009701 See www.foodsafety.govt.nz for registration conditions. Boehringer Ingelheim Animal Health New Zealand Ltd Freephone: 0800 800 822 Batch No.: Expiry Date: Product: Vetmedin 5 mg Chewable Tablets for Dogs Date: 9 March 2018 ACVM No.: A009701 Page 2 of 6 CARTON LABEL PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Vetmedin ® 5 mg Chewable Tablets for Dogs Active Constituent: Each tablet contains 5 mg Pimobendan 50 tablets INDICATIONS Vetmedin ® Chewable Tablets are indicated for: The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DCM) or valvular insufficiency (mitral and/or tricuspid regurgitation). The treatment of preclinical DCM in large breed dogs. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes. Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy. For the treatment of dogs with evidence of increased heart size secondary to asymptomatic (preclinical) myxomatous mitral valve disease to delay the Baca dokumen lengkap